An Expanded Compassionate Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PRO140_CD02 Study
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 05 Sep 2017
At a glance
- Drugs PRO 140 (Primary)
- Indications HIV-1 infections
- Focus Expanded access; Therapeutic Use
- Acronyms CD02_EA
- Sponsors CytoDyn
- 30 Aug 2017 Status changed from suspended to completed.
- 29 Apr 2016 Status changed from planning to suspended.
- 03 Dec 2015 New trial record